Recap: Merck & Co Q3 Earnings

Shares of Merck & Co MRK rose 1.5% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 15.23% over the past year to $1.74, which beat the estimate of $1.43.

Revenue of $12,551,000,000 up by 1.24% year over year, which beat the estimate of $12,170,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $5.91 and $6.01.

The upcoming fiscal year's revenue expected to be between $47,600,000,000 and $48,600,000,000.

How To Listen To The Conference Call

Date: Oct 27, 2020

Time: 08:00 AM

ET Webcast URL: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=53B0CB54-0310-424B-B496-15736D830353&LangLocaleID=1033%20%20%20%20%20&Referrer=https%3A%2F%2Fwww.merck.com%2F

Technicals

52-week high: $92.64

52-week low: $65.25

Price action over last quarter: down 4.48%

Company Description

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.